CHEMOTHERAPY DEVICES MARKET ANALYSIS

Regional Analysis

Global Chemotherapy Devices Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global chemotherapy devices market over the forecast period. North America is estimated to hold 33.5 % of the market share in 2023. The market is expected to witness significant growth in the near future, owing to increasing organic growth strategies such as product approval by regulatory authorities to expand key players’ product portfolio. For instance, in April 2020, UroGen Pharma Ltd., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted expedited approval for Jelmyto(mitomycin) for pyelocalyceal solution, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (LG UTUC).

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa